Trials / NCT06591793
Study of Subretinally Injected AAVB-081 in Patients With Usher Syndrome Type IB (USH1B) Retinitis Pigmentosa
Recruiting now Phase 1 / Phase 2 Gene therapy
- Sponsor
- AAVantgarde Bio Srl
- Treatment
- AAVB-081
- Gene
- MYO7A
- Conditions
- Usher Syndrome, Type 1B
- Ages
- 18 Years to 50 Years
- Enrollment
- 15 participants
- Started
- 2024-07-02
- Main results expected
- 2025-07
- Results posted
- Not yet
- Record last updated
- 2025-05-02
What the study is testing
The purpose of the 081-101 study is to evaluate the safety and tolerability of a single subretinal injection of AAVB-081 in USH1B patients with retinitis pigmentosa due to a mutation in the MYO7A gene. The study will also assess the initial efficacy following AAVB-081 administration.
Where it runs
Italy (1)
- University of Campania Luigi Vanvitelli, Naples (recruiting now)
United Kingdom (2)
- Moorfields Eye Hospital, London (recruiting now)
- Retina Clinic London, London (recruiting now)